Business News • PR NewsWire • PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer

PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer

PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer

MADRID and DUBLIN, Feb. 17, 2020 /PRNewswire/ -- PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the New Drug Application (NDA) seeking accelerated approval for lurbinectedin...

View More : https://www.prnewswire.com:443/news-releases/pharmamar-and-jazz-pharmaceuticals-announce-fda-acceptance-and-priority-rev...

Releted News by prnewswire

37th Niwano Peace Prize Awarded to South Korean Zen Master, Venerable Pomnyun

Verband der Kleidungsproduzenten Kambodschas (GMAC) drückt nach teilweiser Aussetzung des Handelsprogramms „Alles außer Waffen" (EBA) seine Unzufriedenheit mit der Europäischen Union aus

Bublar Group Opens Next Beta Test for Upcoming Launch of Mobile Game Otherworld Heroes

PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer

Arix Bioscience plc : Imara Files for Proposed Initial Public Offering in the United States

Opus Group: Year-end Report 2019

L'Association des fabricants de vêtements du Cambodge (GMAC) exprime son mécontentement à l'égard de l'Union européenne à la suite de la suspension partielle du programme commercial « Tout sauf les armes » (TSA)